Silk Road Medical to Report First Quarter 2021 Financial Results on May 4, 2021
Silk Road Medical (Nasdaq: SILK) has announced it will disclose its financial results for Q1 2021 on May 4, 2021, after the market closes.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silk Road Medical (Nasdaq: SILK) has announced it will disclose its financial results for Q1 2021 on May 4, 2021, after the market closes. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Investors can join the call by dialing (844) 883-3861 domestically or (574) 990-9820 internationally, using conference ID: 9973707. Silk Road Medical focuses on reducing stroke risk through its flagship procedure, TransCarotid Artery Revascularization (TCAR), designed to treat carotid artery blockages.
Details
News Market Reaction – SILK
The recorded move for SILK in the trading session of this news was +5.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2021 after market close on Tuesday, May 4, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by dialing (844) 883-3861 for domestic callers or (574) 990-9820 for international callers, using conference ID: 9973707. A live and archived webcast of the event will be available at https://investors.silkroadmed.com/.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company’s flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
Investor Contact:
Lynn Lewis or Caroline Paul
Gilmartin Group
investors@silkroadmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.